Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suyusu immunonutrition in GI cancer adjuvant chemotherapy
NCT06085365Phase 3Unknown
- Sponsor
- China Medical University
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal tumor (2 arms), sponsored by China Medical University. Primary endpoint: Incidence of chemotherapy related adverse reactions. Status: unknown.
02
Conditions
gastrointestinal tumor
Beyond the preview
Go deeper on NCT06085365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085365.